India has long been a cornerstone in pharmaceuticals and the 100 per cent tariff imposed by US President Donald Trump will not impact the country much, said pharma industry leaders. India would still need to enforce its cost-efficiency strategy, they said.

The Pharmaceutical Exports Promotion Council of India (Pharmexcil) said the 100 per cent tariffs on pharmaceuticals will not impact India much. Indian generic products are, in fact, a cost-saving opportunity for the US, which saves around $200 billion a year from Indian generic imports. The US has enjoyed cost-saving on pharmaceutical generics for the past 10 years, said Pharmexcil. Indian pharma’s biggest strength is its quality and low price points. Advertisement

The council said it expects Indian exports to the US to rise 10-11 per

See Full Page